Pomaglumetad Methionil Anhydrous

Summary

Pomaglumetad Methionil Anhydrous (CHEMBL2110730) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including post-traumatic stress disorder and methamphetamine dependence.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 23
• Chemistry: 366.4 Da · C12H18N2O7S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2110730
Name	Pomaglumetad Methionil Anhydrous
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	25195354
Molecular formula	C12H18N2O7S2
Molecular weight	366.4
InChIKey	VOYCNOJFAJAILW-CAMHOICYSA-N

SMILES: CSCC[C@@H](C(=O)N[C@]1(CS(=O)(=O)[C@@H]2[C@H]1[C@H]2C(=O)O)C(=O)O)N

IUPAC name: (1R,4S,5S,6S)-4-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-2,2-dioxo-2lambda6-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid

Also known as: LY-2140023, Ly2140023, LY2140023, Pomaglumetad methionil anhydrous, POMAGLUMETAD METHIONIL ANHYDROUS, POMAGLUMETAD METHIONIL

Parent form; salt/anhydrous children: CHEMBL2105707

Patent coverage: 78 distinct patent families (194 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
post-traumatic stress disorder	1	MONDO:0005146	EFO:0001358
methamphetamine dependence	1	MONDO:0005419	EFO:0004701
psychotic disorder	1	MONDO:0005485	EFO:0005407

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 23.

Phase distribution

Phase	Trials
PHASE1	12
PHASE2	6
PHASE3	4
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01129674	PHASE2/PHASE3	TERMINATED	A Long-Term, Open-Label, Study on Schizophrenia
NCT01307800	PHASE3	TERMINATED	A Study of LY2140023 in Patients With Schizophrenia
NCT01328093	PHASE3	TERMINATED	A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients
NCT01452919	PHASE3	COMPLETED	A Physical Dependence Study in Schizophrenia
NCT01487083	PHASE3	TERMINATED	A Long-Term Study in Schizophrenia
NCT00149292	PHASE2	COMPLETED	Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo
NCT00520923	PHASE2	COMPLETED	A Study for Patients With Schizophrenia
NCT00845026	PHASE2	COMPLETED	A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
NCT01052103	PHASE2	COMPLETED	A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
NCT01086748	PHASE2	COMPLETED	A Study in Schizophrenia Patients
NCT01125358	PHASE2	TERMINATED	A Study in Schizophrenic Patients
NCT01354353	PHASE1	COMPLETED	A Study of Safety and Tolerability in Subjects With Schizophrenia
NCT01440478	PHASE1	COMPLETED	The Effects of Urinary pH Changes on an Investigational Compound in Healthy Subjects
NCT01475136	PHASE1	COMPLETED	A Study of LY2140023 in Hepatically-Impaired Participants
NCT01524237	PHASE1	COMPLETED	A Study of LY2979165 and LY2140023 in Healthy Volunteers
NCT01591330	PHASE1	COMPLETED	A Study of LY2140023 in Healthy Males and Females
NCT01606436	PHASE1	COMPLETED	A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia
NCT01609218	PHASE1	COMPLETED	A Study of LY2140023 in Healthy Participants
NCT01637142	PHASE1	COMPLETED	A Study of LY2140023 in Healthy Participants
NCT01659177	PHASE1	WITHDRAWN	A Study of LY2140023 in Healthy Participants
NCT02234687	PHASE1	TERMINATED	A mGlu2/3 Agonist in the Treatment of PTSD
NCT03106571	PHASE1	TERMINATED	Study of Pomaglumetad and Methamphetamine
NCT03321617	PHASE1	COMPLETED	Glutamate Reducing Interventions in Schizophrenia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).